Overview

Dose-Proportionality and Food Effect Study of TNX-102 SL

Status:
Completed
Trial end date:
2019-12-24
Target enrollment:
Participant gender:
Summary
This will be a single center, single-dose, randomized, open-label, 3-period, crossover, dose-proportionality and food-effect study.
Phase:
Phase 1
Details
Lead Sponsor:
Tonix Pharmaceuticals, Inc.
Treatments:
Cyclobenzaprine